These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17245215)

  • 1. High plasma osteopontin levels in patients with inflammatory bowel disease.
    Mishima R; Takeshima F; Sawai T; Ohba K; Ohnita K; Isomoto H; Omagari K; Mizuta Y; Ozono Y; Kohno S
    J Clin Gastroenterol; 2007 Feb; 41(2):167-72. PubMed ID: 17245215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response.
    Sato T; Nakai T; Tamura N; Okamoto S; Matsuoka K; Sakuraba A; Fukushima T; Uede T; Hibi T
    Gut; 2005 Sep; 54(9):1254-62. PubMed ID: 16099792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
    Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
    Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease.
    Andoh A; Tsujikawa T; Hata K; Araki Y; Kitoh K; Sasaki M; Yoshida T; Fujiyama Y
    Am J Gastroenterol; 2005 Sep; 100(9):2042-8. PubMed ID: 16128950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis.
    Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F
    Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of soluble CD40 ligand are elevated in inflammatory bowel diseases.
    Ludwiczek O; Kaser A; Tilg H
    Int J Colorectal Dis; 2003 Mar; 18(2):142-7. PubMed ID: 12548417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment.
    Eivindson M; Grønbaek H; Flyvbjerg A; Frystyk J; Zimmermann-Nielsen E; Dahlerup JF
    Growth Horm IGF Res; 2007 Feb; 17(1):33-40. PubMed ID: 17126585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma osteopontin predicts inflammatory bowel disease activities.
    Komine-Aizawa S; Masuda H; Mazaki T; Shiono M; Hayakawa S; Takayama T
    Int Surg; 2015 Jan; 100(1):38-43. PubMed ID: 25594638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
    Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn's disease and diverticulitis.
    Masuda H; Takahashi Y; Asai S; Hemmi A; Takayama T
    J Gastroenterol; 2005 Apr; 40(4):409-13. PubMed ID: 15868372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistin is an inflammatory marker of inflammatory bowel disease in humans.
    Konrad A; Lehrke M; Schachinger V; Seibold F; Stark R; Ochsenkühn T; Parhofer KG; Göke B; Broedl UC
    Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1070-4. PubMed ID: 17998831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease.
    Shinzaki S; Iijima H; Nakagawa T; Egawa S; Nakajima S; Ishii S; Irie T; Kakiuchi Y; Nishida T; Yasumaru M; Kanto T; Tsujii M; Tsuji S; Mizushima T; Yoshihara H; Kondo A; Miyoshi E; Hayashi N
    Am J Gastroenterol; 2008 May; 103(5):1173-81. PubMed ID: 18177457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study.
    Melmed GY; Elashoff R; Chen GC; Nastaskin I; Papadakis KA; Vasiliauskas EA; Liu W; Landers C; Ippoliti AF; Targan SR
    Clin Gastroenterol Hepatol; 2007 May; 5(5):602-8; quiz 525. PubMed ID: 17478347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different regulation of eosinophil activity in Crohn's disease compared with ulcerative colitis.
    Lampinen M; Backman M; Winqvist O; Rorsman F; Rönnblom A; Sangfelt P; Carlson M
    J Leukoc Biol; 2008 Dec; 84(6):1392-9. PubMed ID: 18801925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saliva Interleukin-6 in patients with inflammatory bowel disease.
    Aleksandra Nielsen A; Nederby Nielsen J; Schmedes A; Brandslund I; Hey H
    Scand J Gastroenterol; 2005 Dec; 40(12):1444-8. PubMed ID: 16316893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis.
    Olsen T; Goll R; Cui G; Husebekk A; Vonen B; Birketvedt GS; Florholmen J
    Scand J Gastroenterol; 2007 Nov; 42(11):1312-20. PubMed ID: 17852866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study.
    Hafer A; Krämer S; Duncker S; Krüger M; Manns MP; Bischoff SC
    BMC Gastroenterol; 2007 Sep; 7():36. PubMed ID: 17784949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Yamada M; Kikuyama M; Maruyama Y; Iwaoka Y; Hirayama K; Nagata S; Takai K
    Am J Gastroenterol; 2008 May; 103(5):1210-6. PubMed ID: 18177452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.